Chinese Journal of Antituberculosis ›› 2023, Vol. 45 ›› Issue (7): 651-657.doi: 10.19982/j.issn.1000-6621.20230054
• Original Articles • Previous Articles Next Articles
Cheng Yao, Chen Hongde, Wu Guihui(), Lai Min, Luo Haixia, Cui Kunping, Li Yuke
Received:
2023-02-28
Online:
2023-07-10
Published:
2023-06-29
Contact:
Wu Guihui, Email: Supported by:
CLC Number:
Cheng Yao, Chen Hongde, Wu Guihui, Lai Min, Luo Haixia, Cui Kunping, Li Yuke. Analysis of death related factors in tuberculosis destroyed lung patients undergoing invasive mechanical ventilation[J]. Chinese Journal of Antituberculosis, 2023, 45(7): 651-657. doi: 10.19982/j.issn.1000-6621.20230054
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20230054
因素 | 死亡组(42例) | 存活组(65例) | 统计检验值 | P值 | |||||
---|---|---|---|---|---|---|---|---|---|
年龄(岁,$\bar{x}±s$) | 41.15±10.23 | 43.24±9.61 | t=1.071 | 0.288 | |||||
体质量指数($\bar{x}±s$) | 17.51±1.21 | 17.29±0.93 | t=1.060 | 0.292 | |||||
性别[例(构成比,%)] | χ2=0.734 | 0.392 | |||||||
男性 | 23(54.8) | 41(63.1) | |||||||
女性 | 19(45.2) | 24(36.9) | |||||||
居住地[例(构成比,%)] | χ2=3.370 | 0.066 | |||||||
农村 | 27(64.3) | 30(46.2) | |||||||
城镇 | 15(35.7) | 35(53.8) | |||||||
文化程度[例(构成比,%)] | χ2=0.378 | 0.539 | |||||||
初中及以下 | 16(38.1) | 21(32.3) | |||||||
初中以上 | 26(61.9) | 44(67.7) | |||||||
婚姻情况[例(构成比,%)] | χ2=0.048 | 0.828 | |||||||
已婚 | 28(66.7) | 42(64.6) | |||||||
未婚(离异、丧偶) | 14(33.3) | 23(35.4) | |||||||
吸烟[例(构成比,%)] | χ2=4.136 | 0.042 | |||||||
是 | 32(76.2) | 37(56.9) | |||||||
否 | 10(23.8) | 28(43.1) | |||||||
饮酒[例(构成比,%)] | χ2=0.538 | 0.463 | |||||||
是 | 12(28.6) | 23(35.4) | |||||||
否 | 30(71.4) | 42(64.6) | |||||||
卡介苗接种史[例(构成比,%)] | χ2=0.296 | 0.587 | |||||||
有 | 36(85.7) | 58(84.6) | |||||||
无 | 6(14.3) | 7(10.7) | |||||||
结核病患者接触史[例(构成比,%)] | χ2=0.341 | 0.559 | |||||||
有 | 9(21.4) | 11(16.9) | |||||||
无 | 33(78.6) | 54(83.1) | |||||||
并发症[例(发生率,%)] | |||||||||
咯血 | 7(16.7) | 8(12.3) | χ2=0.402 | 0.526 | |||||
气胸 | 11(26.2) | 9(13.8) | χ2=2.558 | 0.110 | |||||
肺部感染 | 39(92.9) | 55(84.6) | χ2=1.624 | 0.203 | |||||
慢性肺源性心脏病 | 28(66.7) | 26(40.0) | χ2=7.258 | 0.007 | |||||
合并症[例(患病率,%)] | |||||||||
AIDS | 6(14.3) | 5(7.7) | χ2=0.594 | 0.441 | |||||
糖尿病 | 15(35.7) | 12(18.5) | χ2=4.025 | 0.045 | |||||
支气管哮喘 | 9(21.4) | 8(12.3) | χ2=1.588 | 0.208 | |||||
慢性阻塞性肺疾病 | 22(52.4) | 13(20.0) | χ2=12.154 | 0.000 | |||||
慢性肝病 | 9(21.4) | 12(18.5) | χ2=0.142 | 0.706 | |||||
慢性肾病 | 10(23.8) | 8(12.3) | χ2=2.412 | 0.120 | |||||
有创机械通气原因[例(发生率,%)] | |||||||||
急性呼吸衰竭 | 22(52.4) | 15(23.1) | χ2=9.685 | 0.002 | |||||
慢性呼吸衰竭 | 15(35.7) | 22(33.8) | χ2=0.039 | 0.843 | |||||
感染性休克 | 6(14.3) | 8(12.3) | χ2=0.041 | 0.839 | |||||
急性左心功能不全 | 17(40.5) | 14(21.5) | χ2=4.447 | 0.035 | |||||
APACHE-Ⅱ评分a[分,M(Q1,Q3)] | 16.52(11.75,21.25) | 14.52(11.00,17.50) | U=-1.803 | 0.071 | |||||
SOFA评分a(分,$\bar{x}±s$) | 7.37±1.45 | 6.52±2.73 | t=1.854 | 0.067 | |||||
白细胞计数b(×109/L,$\bar{x}±s$) | 10.19±2.33 | 11.05±3.71 | t=1.340 | 0.183 | |||||
血红蛋白水平b(g/L,$\bar{x}±s$) | 89.62±7.11 | 91.57±10.33 | t=1.070 | 0.287 | |||||
血小板计数b(×109/L,$\bar{x}±s$) | 101.53±15.71 | 105.49±20.06 | t=1.082 | 0.282 | |||||
白蛋白水平b(g/L,$\bar{x}±s$) | 25.34±4.22 | 28.71±6.26 | t=3.065 | 0.002 | |||||
CD4+T淋巴细胞计数b[个/μl,M(Q1,Q3)] | 224.45(121.75,332.50) | 271.52(195.50,345.00) | U=-1.933 | 0.048 | |||||
N末端B型钠尿肽前体b[ng/L,M(Q1,Q3)] | 993.45(869.32,1096.61) | 649.26(528.40,789.82) | U=-7.085 | 0.000 | |||||
C反应蛋白b(mg/L,$\bar{x}±s$) | 62.13±15.41 | 69.26±20.02 | t=1.962 | 0.052 | |||||
降钙素原b(μg/L,$\bar{x}±s$) | 4.31±1.94 | 3.82±2.31 | t=1.160 | 0.248 | |||||
氧合指数c(mmHg,$\bar{x}±s$) | 198.52±50.52 | 281.65±70.14 | t=6.642 | 0.000 | |||||
二氧化碳分压c(mmHg,$\bar{x}±s$) | 64.29±10.13 | 60.43±9.61 | t=1.986 | 0.049 | |||||
病原学检测[例(构成比,%)] | χ2=0.187 | 0.666 | |||||||
阳性 | 35(83.3) | 52(80.0) | |||||||
阴性 | 7(16.7) | 13(20.0) |
[1] |
Han D, Lee HY, Kim K, et al. Burden and clinical characteristics of high grade tuberculosis destroyed lung: a nationwide study. J Thorac Dis, 2019, 11(10):4224-4233. doi:10.21037/jtd.2019.09.63.
doi: 10.21037/jtd.2019.09.63 pmid: 31737307 |
[2] |
Bongomin F. Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern. PLoS Pathog, 2020, 16(8):e1008742. doi:10.1371/journal.ppat.1008742.
doi: 10.1371/journal.ppat.1008742 URL |
[3] |
Fawibe AE, Salami AK, Oluboyo PO, et al. Profile and outcome of unilateral tuberculous lung destruction in Ilorin, Nigeria. West Afr J Med, 2011, 30(2):130-135.
pmid: 21984463 |
[4] |
Ruan H, Gong C, Wang J. The efficacy and safety of surgical treatment for patients with tuberculosis destroyed lung with or without chronic pulmonary aspergillosis. World J Surg, 2021, 45(5):1595-1601. doi:10.1007/s00268-021-05969-w.
doi: 10.1007/s00268-021-05969-w |
[5] |
Kim WY, Kim MH, Jo EJ, et al. Predicting mortality in patients with tuberculous destroyed lung receiving mechanical ventilation. Tuberc Respir Dis (Seoul), 2018, 81(3):247-255. doi:10.4046/trd.2017.0126.
doi: 10.4046/trd.2017.0126 URL |
[6] |
Galvin J, Tiberi S, Akkerman O, et al. Pulmonary tuberculosis in intensive care setting, with a focus on the use of severity scores, a multinational collaborative systematic review. Pulmonology, 2022, 28(4):297-309. doi:10.1016/j.pulmoe.2022.01.016.
doi: 10.1016/j.pulmoe.2022.01.016 pmid: 35227650 |
[7] |
史志国, 宋艳华, 李凌海, 等. 保护性肺通气模式在结核性毁损肺全肺切除术麻醉中的价值. 中国防痨杂志, 2019, 41(5):488-493. doi:10.3969/j.issn.1000-6621.2019.05.005.
doi: 10.3969/j.issn.1000-6621.2019.05.005 |
[8] | 中华人民共和国国家卫生和计划生育委员会. WS 288—2017 肺结核诊断. 2017-11-09. |
[9] | 中华医学会重症医学分会. 机械通气临床应用指南(2006). 中国危重病急救医学, 2007, 19(2):65-72. |
[10] | 隆云, 陈德昌, 马朋林. 实用重症感染学. 北京: 人民卫生出版社, 2021:504-505. |
[11] |
Wang JL, Yin QY, Han C, et al. Risk factors for death in tuberculosis patients requiring ICU care. Epidemiol Infect, 2021, 149:e22. doi:10.1017/S0950268820003106.
doi: 10.1017/S0950268820003106 URL |
[12] |
Thomas L, Chacko B, Jupudi S, et al. Clinical profile and outcome of critically ill patients with tuberculosis. Indian J Crit Care Med, 2021, 25(1):21-28. doi:10.5005/jp-journals-10071-23503.
doi: 10.5005/jp-journals-10071-23503 URL |
[13] |
Sailaja K, Rao HN. Study of pulmonary function impairment by spirometry in post pulmonary tuberculosis. J Evol Med Dent Sci, 2015, 4(42):7365-7371. doi:10.14260/jemds/2015/1068.
doi: 10.14260/jemds/2015/1068 |
[14] |
Hsu D, Irfan M, Jabeen K, et al. Post tuberculosis treatment infectious complications. Int J Infect Dis, 2020, 92S:S41-S45. doi:10.1016/j.ijid.2020.02.032.
doi: 10.1016/j.ijid.2020.02.032 pmid: 32114203 |
[15] | Gayathri SR. Prevalence and Risk Factors for Pulmonary Artery Hypertension and Corpulmonale in Post Tuberculosis Pulmonary Sequelae. Tirunelveli: Tirunelveli Medical College, 2020. |
[16] |
Kumar NP, Fukutani KF, Shruthi BS, et al. Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity. Elife, 2019, 8:e46477. doi:10.7554/eLife.46477.
doi: 10.7554/eLife.46477 URL |
[17] |
van Kampen SC, Wanner A, Edwards M, et al. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. BMJ Glob Health, 2018, 3(4):e000745. doi:10.1136/bmjgh-2018-000745.
doi: 10.1136/bmjgh-2018-000745 URL |
[18] |
Tiberi S, Torrico MM, Rahman A, et al. Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. J Bras Pneumol, 2019, 45(2):e20180324. doi:10.1590/1806-3713/e20180324.
doi: 10.1590/1806-3713/e20180324 URL |
[19] |
Muthu V, Agarwal R, Dhooria S, et al. Outcome of critically ill subjects with tuberculosis: systematic review and meta-analysis. Respir Care, 2018, 63(12):1541-1554. doi:10.4187/respcare.06190.
doi: 10.4187/respcare.06190 pmid: 30206126 |
[20] |
Rasmin M, Elhidsi M, Prasenohadi, et al. Underlying diseases and in-hospital mortality of acute respiratory failure patients: Indonesian prospective cohort study. J Nat Sc Biol Med, 2021, 12(1):22-22. doi:10.4103/jnsbm.JNSBM_127_20.
doi: 10.4103/jnsbm.JNSBM_127_20 URL |
[21] |
Park JH, Na JO, Kim EK, et al. The prognosis of respiratory failure in patients with tuberculous destroyed lung. Int J Tuberc Lung Dis, 2001, 5(10):963-967.
pmid: 11605892 |
[22] |
程耀, 陈洪德, 吴桂辉, 等. 成都市某医院结核重症监护室TB/HIV感染患者死亡相关因素分析. 临床肺科杂志, 2022, 27(11):1746-1750. doi:10.3969/j.issn.1009-6663.2022.11.023.
doi: 10.3969/j.issn.1009-6663.2022.11.023 |
[1] | Senior Department of Tuberculosis, the th Medical Center of Chinese PLA General Hospital, Editorial Board of Chinese Journal of Antituberculosis, Tuberculosis Control Branch of China Intrnational Exchange and Promotive Association for Medical and Health Care. Expert consensus on the diagnosis and treatment of superficial lymph node tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 531-542. |
[2] | Li Xiang, Qi Min, Jiang Jianjie, Wei Jialu, Fu Xuwen, Li Haiwen, Zhang Le. Analysis of risk factors for acute cerebral infarction combined with intracranial tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 499-506. |
[3] | Meiheriban·Maimaiti , Mawlanjan·Emam , Lu Dongmei, Zheng Yanling, Zhang Xueliang, Peng Xiaowang. Study on the effect of daily average temperature on the incidence of tuberculosis in Shufu County at Xinjiang, based on a distributed lag nonlinear model [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 507-513. |
[4] | Bao Shengjuan, Shao Lingling, Wang Jing, Han Xiqin, Huang Hairong, Duan Hongfei. Analysis of therapeutic effects and factors affecting treatment outcomes of Mycobacterium abscessus subspecies abscessus pulmonary disease for 6 months [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 349-354. |
[5] | National Clinical Research Centre for Infectious Disease/The Third People’s Hospital of Shenzhen, Peking University Shenzhen Hospital, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Shenzhen Key Laboratory of Inflammatory and Immune Diseases. Expert consensus on diagnosis and treatment of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 869-879. |
[6] | ZHONG Qian-hong, MA Xiao-hui, ZHONG Yong-hui, ZHAO Zhi-meng, ZHANG Xi-lin, XU Bang, LUO Jie-ying, ZHONG Li-ping, DAI Lei. Analysis of recurrence rate of pulmonary tuberculosis patients in Foshan and the influencing factors from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 690-697. |
[7] | GAO Li, PANG Xue-wen, ZHANG Guo-qin, LI Jing-xin, ZHANG Fan. Analysis of risk factors for recurrence within 2 years after successful treatment of newly treated active pulmonary tuberculosis in Tianjin [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 698-703. |
[8] | TIAN Na, CHU Hong-qian, SUN Zhao-gang. Recent progress of Nano-drug delivery system for tuberculosis treatment [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 732-737. |
[9] | The Joint Tuberculosis Professional Branch of Chinese Antituberculosis Association, The Western China Bone Tuberculosis Union, The North China Union of Bone Tuberculosis. Expert consensus on the diagnosis and treatment of Brucella spondylitis [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 531-538. |
[10] | CHEN Zhi, LIANG Jian-qin. Expert consensus on nutritional assessment and nutritional support treatment for patients with severe tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 421-432. |
[11] | ZHUANG Li, LU Zhen-hui, CEN Jun, MA Zi-feng, LI Cui, JIANG Yu-wei, ZHANG Hui-yong, ZHANG Shun-xian. Establishment and prediction of autoregressive integrated moving average model of monthly reported deaths of pulmonary tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 375-380. |
[12] | Shen Hongcheng, Du Yuhua, Zhang Danni, Wu Guifeng, Lei Yu, Xiao Xincai, Liu Jianxiong. Analysis of drug resistance situation and influencing factors among high-risk group of drug-resistant tuberculosis in Guangzhou, 2014—2019 [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1279-1287. |
[13] | Li Shuolan, Li Mingwu, Li Guangmei, Wang Lin, Wan Rong, Ma Meng. Influencing factors of getting unfavorable treatment outcomes of patients with multidrug-resistant pulmonary tuberculosis in China: a Meta-analysis [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1303-1313. |
[14] | Yuan Yuan, Lu Shuihua. Interpretation of WHO consolidated guidelines on tuberculosis Module 4: Treatment of drug-susceptible tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(11): 1122-1125. |
[15] | Cao Fu, Ma Xiaohong, Ma Tian, Luo Jian, Zhong Xinxin, Feng Junlan, Li Xiaojuan, Liang Zhengen, Zhang Qizhen. Effects of meteorological factors and air pollutants on the incidence of pulmonary tuberculosis in Yulin from 2017 to 2021 [J]. Chinese Journal of Antituberculosis, 2022, 44(11): 1154-1161. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||